Ramseger, R; White, R; Kroger, S
Transmembrane Form Agrin-induced Process Formation Requires Lipid Rafts and the Activation of Fyn and MAPKJOURNAL OF BIOLOGICAL CHEMISTRY. Bd. 284. H. 12. 2009 S. 7697-7705
Firat, E; Tsurumi, C; Gaedicke, S et al.
Tripeptidyl Peptidase II Plays a Role in the Radiation Response of Selected Primary Cell Types but not Based on Nuclear Translocation and p53 StabilizationCANCER RESEARCH. Bd. 69. H. 8. 2009 S. 3325-3331
Zenker, S; Atreya, I; Becker, C et al.
Vav1 Acts As An Essential Modulator in Colitis Associated Colon CancerGASTROENTEROLOGY. Bd. 136. H. 5. 2009 S. A466-A466
Tsurumi, C; Firat, E; Gaedicke, S et al.
Viability and DNA damage responses of TPPII-deficient Myc- and Ras-transformed fibroblastsBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. Bd. 386. H. 4. 2009 S. 563-568
Eberle, T; Doganci, B; Kramer, HH et al.
Warm and cold complex regional pain syndromes: differences beyond skin temperature?Neurology. Bd. 72. H. 6. 2009 S. 505-12
Mitz, SA; Reuss, S; Folkow, LP et al.
When the brain goes diving: glial oxidative metabolism may confer hypoxia tolerance to the seal brainNeuroscience. Bd. 163. H. 2. 2009 S. 552-60
Witan, H; Gorlovoy, P; Kaya, AM et al.
Wild-type Cu/Zn superoxide dismutase (SOD1) does not facilitate, but impedes the formation of protein aggregates of amyotrophic lateral sclerosis causing mutant SOD1.Neurobiol Dis. Bd. 36. H. 2. 2009 S. 331-42
Price, DA; Martinez, AA; Seillier, A et al.
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseEUROPEAN JOURNAL OF NEUROSCIENCE. Bd. 29. H. 11. 2009 S. 2177-2186
Geber, C; Scherens, A; Pfau, D et al.
Zertifizierungsrichtlinien fur QST-Labore.Schmerz. Bd. 23. H. 1. 2009 S. 65-9
Ricken, C; Kuhlmann, C; Luhmann, H et al.
: Inhibition der Myosin-leichte-Kette-Kinase verhindert die Entstehung eines Hirnödems nach experimentellem SchädelhirntraumaAnästhesiologie und Intensivmedizin Abstract. H. CD. 2008 S. PO 3.3.1